Background {#Sec1}
==========

Lynch syndrome (LS) is an autosomal dominantly inherited cancer syndrome predisposing to colorectal cancer (CRC) and several extra-colonic malignancies \[[@CR1]\]. It is the most common hereditary cause of CRC, accounting for about 3% of the disease. LS is caused by constitutional pathogenic variants of any of four DNA mismatch repair (MMR) genes (*MLH1, MSH2, PMS2* and *MSH6*) or by a deletion in the *EPCAM* gene which leads to *MSH2* inactivation. In mutation carriers, a somatic mutation affecting the second allele leads to defective MMR activity.

Based on the international Prospective Lynch Syndrome Database (PLSD) we have demonstrated that stringent current screening guidelines do not protect fully against the development of colorectal cancer (CRC) in *path_MMR* carriers. This observation is despite undertaking colonoscopies with polypectomies every 3 years or even more frequently \[[@CR2]\]. This finding is in contrast to the declared goal of the guidelines \[[@CR1]\] that follow-up by colonoscopy and polypectomy aims to prevent CRC -- an outcome that we expected to be true when issuing these guidelines. Nonetheless, LS patients undergoing surveillance often survive their first cancer and many develop subsequent cancers, again with a good prognosis, albeit a CRC mortality rate of approximately 10%.

There are many possible reasons why CRC continued to occur in our previously reported series despite follow-up with colonoscopy and polypectomy. These reasons include too great an interval between colonoscopies (Table [1](#Tab1){ref-type="table"}). A high rate of interval CRCs in LS patients having surveillance with screening intervals of over 3 years previously prompted those involved in revising guidelines to recommend shorter surveillance intervals \[[@CR1], [@CR3]--[@CR11]\]. This change was based upon the assumption that a major cause of interval cancers was a fast transition from visible adenomatous polyp to cancer as a consequence of the increased mutation rate associated with MMR deficiency \[[@CR12]\]. A 3-year interval between colonoscopies has been shown to reduce the CRC incidence and mortality in LS in a comparative prospective study \[[@CR3]\]. However, previous relevant studies \[[@CR3]--[@CR7], [@CR13]--[@CR18]\] (summarized in Table [2](#Tab2){ref-type="table"}) have provided no definite empirically observed evidence to support what interval between colonoscopies might best prevent CRC in LS, and how protective such an intervention might be.Table 1National surveillance protocols for colorectal and endometrial cancerCenterSeries cencoredColonoscopyGynecological examinationReference no. and additional detailsIntervalFrom-toIntervalFrom-toModalities in addition to clinical examinationFinland20143 years1985--20141 year1995-2014EB, ultrasound, CA12-5\[[@CR3], [@CR4], [@CR8]\]Denmark20142 years1991--20142 years1991-2014US\[[@CR9]\]Germany20141 year1995--20141 year1995-2014US\[[@CR10], [@CR17]\]Italy20131-2 years (1 year when age \> 40 years; adenoma)1990--20132 years (1 years when age \> 35 yrs.)1990-2013US, Pap smear\[[@CR11]\]UK (Manchester)20142 years1994--20141 year1990-2014Hysteroscopy, US, CA12-5\[[@CR6]\]Sweden20142 years1990--20001 year1992-2014US, CA 12-5.Some patients: EB\[[@CR25], [@CR26]\]18 months2000--2014Australia20141 year1990--20141 year1990-2005US, EB, CA12-5<https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp106_0.pdf>\
<https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp106_0.pdf>2005-2014Risk reducing surgery onlySpain20131-2 years (1 year when age \> 40 years)1999--20131 year1999-2013USUnpublishedThe Netherlands20132-3 years1987--19961-2 years1994-2005US\[[@CR7]\]2 years1997--20131-2 years2005-2013US, EBUK (Cardiff)20133 years1991--19941 year1998-2010US, CA12-5(3 or 4 monthly)Unpublished\
Colonoscopy 96% compliance with interval.2 years1994--2013Gyn: only 27% of eligible women had gyn. Cancer screening. Since 2010 not systematic.UK (Newcastle)20142 years1995--2014No fixedUnpublishedNorway20133 years1989--19962 years1989-2013US, CA12-5\[[@CR5]\]2 years (one year when adenoma)1996--2013*US* Transvaginal ultrasound*EB* Endometrial biopsy Table 2Studies assessing the effect of colonoscopy surveillance interval in LSStudyRef.SubjectsInclusion criteriaSettingCS IntervalFindingsJärvinen, 2000\[[@CR3]\]252Amsterdam criteria and LS, gene testedProspective, controlled non-randomized trial3 yearsCRC reduced 62% in 15 years compared to not screened.Mortality reduced 65% vs. no CS surveillance. Adherence 93%.Dove-Edwin, 2005\[[@CR13]\]290Amsterdam criteriaRetrospective3 yearsEstimated 72% reduction of CRC mortality when screened. Adherence not reported.Mecklin, 2007\[[@CR4]\]420LS, gene testedProspective, observational3 yearsEstimated risk for CRC 22% for women and 35% for men before age 60. No increase in CRC mortality compared to non-carriers. Adherence 98%.Järvinen, 2009\[[@CR14]\]242LS, gene testedProspective, controlled non-randomized observational3 yearsCRC incidence 12.4% in 11·5 years, no increase in CRC mortality compared to non-carriers. Adherence 96%.De vos tot Nederveen Cappel, 2002\[[@CR15]\]857Amsterdam criteria or gene testedRetrospective2-3 years10.5% cumulative CRC risk in 10 years under surveillance. Lower tumor stage if CS interval \< 2 years.Stormorken, 2007\[[@CR5]\]601Amsterdam criteria or gene testedProspective, observational2-3 yearsCRC incidence of LS carriers not increased compared to non-carriers. Adherence not reported.Newton, 2015\[[@CR6]\]227LS, gene testedRetrospective2-3 yearsCRC incidence 25% at age 70. Adherence 87%.Stupart, 2009\[[@CR16]\]178LS, *MLH1* mutationProspective, controlled non-randomized observational1-2 yearsCRC incidence 11% in 5 years compared to 27% if no surveillance. Adherence not reported.Vasen, 2010\[[@CR7]\]745LS, gene testedRetrospective1-2 yearsCRC cumulative risk 6% in 7·2 years. Adherence not reported.Engel, 2010\[[@CR17]\]622LS, gene testedProspective, controlled non-randomized observational1-2 yearsCRC cumulative risk at age 60 23%, early stages. Adherence 81% to 15 months.Stuckless, 2012\[[@CR18]\]152LS, *MSH2* mutationRetrospective1-2 yearsCRC reduced 71% in 10 years, interval cancers 27% in males and 15% in females. Adherence 44%.*LS* Lynch syndrome*CRC* colorectal cancer*CS* colonoscopy

Among LS patients in our previous reports from PLSD, *path_MLH1* carriers had the highest incidence of CRC despite surveillance colonoscopy, making them the best cohort to examine why CRC continued to occur. The first hypothesis considered was that the large number of carriers reported in PLSD who were from Finland represented a potential confounder. The high overall incidence of CRC observed in *path_MLH1* carriers in PLSD might have arisen because Finland, unlike other countries, had not shortened the recommended interval between colonoscopies from the original 3 year interval advocated many years ago.

Here we report whether or not the high CRC incidence in *path_MLH1* carriers despite colonoscopy surveillance was caused by a high incidence in Finland and investigate time to CRC cancer since last colonoscopy and overall survival.

Methods {#Sec2}
=======

The Prospective Lynch syndrome database {#Sec3}
---------------------------------------

PLSD contains data stored as an Oracle© relational database. Details on data storage and manipulation have been described in detail earlier \[[@CR2]\]. Patients who were subject to prospective follow-up including colonoscopy were reported from LS registries in 13 centers in Europe and Australia. In some cases screening for early detection of endometrial and ovarian cancer were also implemented. Details on the guidelines followed at each contributing center are given in Table [1](#Tab1){ref-type="table"}.

Study design {#Sec4}
------------

The design was a prospective, case-based, open observational study of *path_MLH1* carriers subjected to colonoscopy comparing two groups with different recommended intervals between colonoscopies. The prospective observations recorded included follow-up from first prospectively planned and carried out colonoscopy onwards. Patients with any cancer prior to, or at the age of first colonoscopy (prevalent cancers) were excluded, as were subjects with less than 1 year of prospective observation. The following observations were used: age at first colonoscopy, gender, age at last observation, months from last completed colonoscopy to diagnosis of CRC, age at any cancer together with the ICD diagnosis of the cancer, and age at death.

Inclusion criteria {#Sec5}
------------------

All patients included had been subject to prospective follow-up with colonoscopy because of their increased risk for CRC. All were confirmed carriers of *path_MLH1* variants by genetic testing. All *path_MLH1* variants were checked against the LOVD database ([http://chromium.lovd.nl/LOVD2/colon_cancer/](http://chromium.lovd.nl/LOVD2/colon_cancer)). Please see our previous report for a more detailed description of inclusion criteria \[[@CR2]\].

Time between colonoscopies in the different centers {#Sec6}
---------------------------------------------------

All subjects were offered planned regular surveillance colonoscopy and polyp removal according to the guidelines followed at each reporting center (Table [1](#Tab1){ref-type="table"}). The recommended colonoscopy interval in the Finnish national registry protocol was 3 years throughout the study period. From 1997 onwards, all the other centers recommended surveillance intervals of 2 years or less. Thus, only observations from 1997 onwards were included in the present study. Each center kept track of their activities through medical files and/or research registries, and all were able to contribute complete reports for all patients included with no missing values. Whilst these methods do not conform to the stringency of a clinical trial they nonetheless represent the best that can be achieved by a collaborative group of highly interested expert clinicians working in diverse health service systems.

Surveillance for extra-colonic cancers {#Sec7}
--------------------------------------

Patients in the contributing centers were informed of general cancer awareness but the surveillance for extra-colonic cancers varied across the centers (Table [1](#Tab1){ref-type="table"}).

Cancer treatment {#Sec8}
----------------

All cancers were treated according to local standards. Treatment modalities were not considered.

Events scored {#Sec9}
-------------

All infiltrating CRCs were scored using the first three positions in the ICD-9 system. Age at each cancer was recorded. Age at death was recorded.

Annual and cumulative incidence rates {#Sec10}
-------------------------------------

Each patient was observed from age at inclusion to age at last observation or first cancer. For each patient, the number of years observed in each five-year group from 25 years of age onwards was counted. All first cancers were scored according to the age at diagnosis. Annual incidence rates (AIR) for age groups were calculated by dividing the number of cancers observed by the total number of observation years. Each patient was counted once only, irrespective of how many synchronous cancers the patient might have had as first cancers. Later cancers were not considered. Cumulative incidence, denoted by Q, was computed starting at age 25, assuming zero incidence before age 25, using the formula Q(age) = Q(age-1) + \[1-Q(age-1)\]·AIR(age) where AIR(age) is the annual incidence for the corresponding 5 year interval. The hazard rate H = −ln\[1-AIR\] was used with standard error estimated as SEH = SEAIR/(1-AIR). The standard error, denoted by SEQ, was computed in two steps and 95% confidence intervals were estimated. Follow-up continued after the occurrence of first cancers, and all patients were either reported to be alive or validated to be alive in a population register when censored. See our previous report \[[@CR2]\] for a more detailed description of these methods. Differences in time-to-events were also calculated by the Kaplan-Meier algorithm and Mantel-Cox *p*-values when appropriate.

Survival {#Sec11}
--------

Crude survival was calculated by the Kaplan-Meier algorithm and Mantel-Cox p-values as time from first cancer to last observation/death. Cancer stages at diagnosis and causes of death were not considered in this report.

Results {#Sec12}
=======

There were 7924 observation years in the final analysis from 430 males and 514 females (*n* = 944). The Finnish series included 4625 and the non-Finnish series 3299 observation years after first colonoscopies. Ages at inclusion were similar for both series (35.2 years and 36.1 years, respectively; *p* \> 0.05). Baseline characteristics of the study population and the classification of *path_MLH1* variants are presented in Table [3](#Tab3){ref-type="table"}.Table 3Baseline characteristics of the study populationAll subjects3-year interval (Finnish)1-2-year interval (non-Finnish)Observation years792846253299Number of subjects944505439GenderMale430246 (48.7%)184 (41.9%)Female514259 (51.3%)255 (58.1%)Age at inclusion(Mean, SD)35.5 (11.7)35.2 (12.1)36.1 (11.0)Follow-up time(Mean, SD)8.4 (5.7)9.2 (5.9)7.5 (5.2)*SD* standard deviation

Classification of *path_MLH1* variants {#Sec13}
--------------------------------------

Seven hundred and six (75%) of the patients carried *path_MLH1* variants found in LOVD, and 238 of variants (25%) were not found in LOVD. Among the 706 found in LOVD, 691 (98%) were pathogenic (class 5) and 15 (2%) were probably pathogenic (class 4). Among the 505 in the Finnish series 406 (80%) and four (0.7%) had class 5 and class 4 variants, Among the non-Finnish series 285 (65%) had class 5 and 11 (2.5%) class 4 variants in LOVD, Among the 238 variants not reported to LOVD 95 were detected in the Finnish series and 143 in the non-Finnish series. All of them were eventually classified as class 5 and 4 based on the combined assessment of two of the co-authors (IF, JS) following the updated InSight rules \[[@CR19]\].

Cumulative incidences of cancers {#Sec14}
--------------------------------

A total of 101 CRCs and 83 extra-colonic cancers were diagnosed during the follow-up period. Despite less frequent colonoscopy, the cumulative incidences of CRC were modestly lower for the Finnish series compared to the non-Finnish series in all age groups (39.2%; 95% confidence interval 29.4--48.9 vs 53%; 39.6--68) but not significantly so. Regarding extra-colonic cancers, similar observations were made (39.7%; 28.2--51.2 vs 57.2%; 41--73.5, respectively). The cumulative incidence rates categorized by 10-year intervals from age 25 are shown in Table [4](#Tab4){ref-type="table"} and Fig. [1a](#Fig1){ref-type="fig"} and [b](#Fig1){ref-type="fig"}. Additional file [1](#MOESM1){ref-type="media"}: Table S1 presents the annual incidence rates of cancers categorized by five-year intervals from 25 to 70 years.Table 4Cumulative incidences from 25 years of age and 95% confidence intervals for colorectal cancer and extra-colonic cancer3-year interval (Finnish)1-2-year interval (non-Finnish)Current ageAge stopObs years\#CaCumulative incidence (%)95% CIObs years\#CaCumulative incidence (%)95% CIColorectal cancer All  254019821912.9\[7.4--18.3\]12991716.4\[9.2--23.7\]  255033014025.4\[18.6--32.3\]24243630.0\[21.7--38.3\]  256040704731.7\[24.0--39.4\]29354844.9\[34.6--55.2\]  257043305139.2\[29.4--48.9\]30945053.8\[39.6--68.0\] Male  254010261215.7\[7.5--23.9\]610918.5\[7.2--29.7\]  255016822530.8\[20.7--40.9\]11102137.0\[24.3--49.8\]  256020752936.9\[26.1--47.7\]12882857.8\[41.5--74.0\]  257021893041.1\[28.2--54.0\]13652857.8\[41.5--74.0\] Female  254095679.6\[2.8--16.4\]689814.8\[5.3--24.4\]  255016231519.4\[10.6--28.3\]13141524.1\[13.4--34.8\]  256020101826.2\[15.2--37.2\]16462035.2\[22.0--48.3\]  257021562136.4\[22.1--50.6\]17292255.3\[30.5--80.0\]Extra-colonic cancer All  2540198242.7\[0.1--5.3\]129932.9\[0.0--6.1\]  255033012416.9\[10.7--23.2\]24242217.8\[11.0--24.6\]  256040703932.2\[23.5--40.9\]29343535.3\[24.8--45.7\]  257043304239.7\[28.2--51.2\]30944157.2\[41.0--73.5\]*Obs years* observation years at age group*\#Ca* number of cancers during observation*CI* confidence interval Fig. 1**a** Calculated cumulative incidence for colorectal cancer in the 3-year and non-Finnish series. Fin = Finnish series (blue line). Oth = non-Finnish series (green line). **b** Calculated cumulative incidence for extra-colonic cancer in the 3-year and non-Finnish series. Fin = Finnish series (blue line). Oth = non-Finnish series (green line). **c** Calculated cumulative incidence for colorectal cancer by gender in the 3-year and non-Finnish series. Fin_M = Finnish series, males (blue line). Fin_F = Finnish series, females (red line). Oth_M = non-Finnish series, males (green line). Oth_F = non-Finnish series, females (orange line)

The similar age of inclusion allowed us to make comparisons of time from inclusion to diagnosis of CRC using the Kaplan-Meier algorithm. In the Finnish series, 3 and 11% of carriers were diagnosed with CRC after 5 and 10 years of follow-up, respectively, compared to 5 and 14%, respectively in the non-Finnish series (*p* \> 0.05). The differences were modestly larger in males than in females (Fig. [1c](#Fig1){ref-type="fig"}). The percentages of carriers developing extra-colonic cancers were also similar: 3 and 9% at 5 and 10 years after inclusion in the Finnish series compared to 3 and 11% in the non-Finnish series (p \> 0.05). In sum, none of the differences were significant and all point estimates were similar or lower in the Finnish series.

Correlation with population incidence of CRC {#Sec15}
--------------------------------------------

Next, we explored the correlation between observed CRC incidences in *path_MLH1* LS patients and the corresponding population incidences of CRC. The relative incidence of CRC in the Finnish population compared to the other countries was 0.80 \[the age-standardized incidence rate in Finland was 35.0 per 100,000 versus a mean of 43.6 per 100,000 for the other reporting countries ([http://eco.iarc.fr/EUCAN/](http://eco.iarc.fr/EUCAN); downloaded October 2015)\]. By comparison, the observed ratio of cumulative risk for CRC at 70 years in the Finnish series of *path_MLH1* carriers compared to the others was similar: 0.72 (39.2% in the Finnish series versus the average of 54.8% in other countries combined).

Time since last colonoscopy to CRC and survival {#Sec16}
-----------------------------------------------

The mean time from last colonoscopy to CRC did not differ between the Finnish and non-Finnish series irrespective of the interval between colonoscopies. It was 32.7 (SD 13.6) months for the Finnish series and 31.0 (SD 23.4) months for the non-Finnish series (p \> 0.05). Times since last colonoscopy to CRC in the two series by 6 months periods are shown in Table [5](#Tab5){ref-type="table"}. Of note, the rates of interval cancers occurring before the next planned 2-yearly or 3-yearly colonoscopy were similar in both series at 56.9% and 50% in the Finnish and the others respectively (Table [5](#Tab5){ref-type="table"}).Table 5Months since last colonoscopy with no cancer to colorectal cancer diagnosed3-year interval (Finnish)1-2-year interval (non-Finnish)Months since last colonoscopyNumber CRCCumulative number CRCCumulative %Number CRCCumulative number CRCCumulative %\<6000%000%7--11223.9%5510%12--17359.8%131836%18--234917.6%72550%24--29172651%63162%30--3532956.9%43570%36--41144384.3%33774%42--4734690.2%34080%48--120551100%1050100%*CRC* colorectal cancer

Moreover, there were no differences in the survival of CRC in *MLH1* carriers in the two series. Five- and ten-year overall survival after CRC was 90% (95% confidence interval: 78-96%) and 88% (75-95%), respectively, in the Finnish series compared to 96% (85-99%) and 91% (78-97%) in the 1-2-year interval series (p \> 0.05). There were not enough deaths for meaningful stratification by time since last colonoscopy with respect to survival. Finally, there were no differences in survival of extracolonic cancers. Five- and ten-year survival after extra-colonic cancer was 79% (64-89%) and 79% (64-89%), respectively, in the Finnish series compared to 82% (68-92%) and 82% (69-92%) in the 1-2-year interval series (p \> 0.05).

Discussion {#Sec17}
==========

This study showed that the high incidence of CRC observed in our combined international series of *path_MLH1* carriers was not caused by a higher incidence in the Finnish series compared to the others. In contrast to what we expected, the CRC incidence in the Finnish series was lower than in the others, but not significantly so.

First, we considered the possibility that the trend towards a lower CRC incidence in the Finnish series could reflect the lower population incidence of CRC in Finland. In fact, the observed ratio of cumulative risk for CRC at 70 years showed a similar pattern in the Finnish and non-Finnish series. Disease expression differences between Finnish and non-Finnish *path_MLH1* carriers could reflect population-specific environmental and behavioural factors or a lower penetrance of the Finnish founder *path_MLH1* variants compared to other *path_MLH1* variants but this study shows that these factors cannot have a major impact on the observed high cumulative risk of CRC in *path_MLH1* carriers in the total PLSD cohort of *path_MLH1* patients.

Secondly, we examined whether or not the Finnish patients were actually colonoscoped less frequently than the others. We found that the time between last colonoscopy and CRC was similar for both series irrespective of the recommendations in place. Also, it was evident that a proportion of CRCs in both series could be classified as interval cancers (Table [5](#Tab5){ref-type="table"}). In particular, the rates of interval cancers that occurred before the planned next 2-yearly or 3-yearly colonoscopy were 56.9% and 50% in the Finnish series and the others, respectively (Table [5](#Tab5){ref-type="table"}). While the organizational aspects of surveillance at the non-Finnish centers were heterogenous and details that might impact our observations were not readily available, the organization of surveillance in the Finnish series displays two key features that are critical for the interpretation of our findings: there are special and dedicated booking and call back systems in place to follow all identified LS carriers and the reported adherence to colonoscopy intervals has been consistently very high throughout the years \[[@CR4], [@CR8]\]. Thus, in the Finnish series non-compliance/adherence with local surveillance guidelines cannot explain the occurrence of all cancers and the pattern of time from last colonoscopy to CRC suggests that only a limited proportion of CRCs would have been prevented by reducing the interval from 3 to 2 years.

Our study has a number of strengths including: (i) a large number of observation years; (ii) a focus on *path_MLH1* carriers showing a high cumulative risk thereby avoiding mixing of carriers of *path_MMR* variants in different MMR genes and (iii) the robustness of the dataset collated based upon prospectively observed outcomes. On the other hand, several limitations need to be highlighted: (i) in spite of the number of observation years included our sample size is still limited. Stochastic variation cannot be completely ruled out and our observations do not exclude a significant impact of differences in population prevalence of CRC on LS expressivity; and (ii) only a detailed analysis of the interval, quality and reported findings of the colonoscopies will allow a refined assessment of the impact of this confounder. However, such an analysis will not change the critical observation that time between colonoscopy and CRC is essentially the same in both series.

The prospective health outcome observations presented here challenge the dogma that the performance of very frequent colonoscopies, many of them performed in expert centers, has a strong primary preventive effect on CRC incidence in LS. It is notable that despite surveillance, the expert centers with good recall systems in place that have contributed their data to this study have not succeeded in preventing CRC as has been achieved in non-LS familial CRC \[[@CR20]\]. Consequently, our observations set the foundations for a more detailed analysis of the determinants of this lack of success. In this regard, there is biological evidence that CRC in LS may arise directly without a precursor polyp although the relative contribution of this distinct natural history to the totality of CRCs observed is a matter of controversy \[[@CR21]--[@CR24]\]. Thus, it is possible that even colonoscopies achieving the best quality standards would not be able to prevent all CRCs in LS.

Whether shorter colonoscopy interval could result in lower CRC stage needs to be addressed in future studies with cancer stage included. We are in the process of expanding our database in this regard.

Conclusions {#Sec18}
===========

In summary, we tested whether or not the high incidence of CRC in *path_MLH1* carriers observed in our previous reports was caused by a distinct high incidence in the Finnish series in which 3-yearly colonoscopy was recommended. In the present report we show that the cumulative risk of CRC is high for *path_MLH1* carriers undergoing colonoscopic surveillance irrespective of the specific characteristics of their country of origin and the associated factors that may have an impact on the expression of the disease. The contribution of more observation years from countries with different population CRC incidences will be needed to formally test the hypothesis that population CRC incidence correlates with LS expression. The lack of a difference in the time between last colonoscopy and CRC in the two series investigated in this study challenges current beliefs regarding colonoscopy intervals in LS surveillance. Our findings mandate a detailed study that will eventually inform policy makers. Finally, in view of the excellent 10-year overall survival in the Finnish and non-Finnish series we remain strong advocates of current surveillance practices for those with LS pending studies that will inform new recommendations on the best surveillance interval.

Additional file {#Sec19}
===============

Additional file 1: Table S1.Annual incidence rates (AIR) and 95% confidence intervals for colorectal cancer and extra-colonic cancer. (DOCX 15 kb)

AIR

:   Annual incidence rate

CI

:   Confidence interval

CRC

:   Colorectal cancer

ICD9

:   International Classification of Disease, 1975 revision.

InSiGHT

:   International Society for Gastrointestinal Hereditary Tumours

LOVD

:   Leiden Open Variation Database

LS

:   Lynch Syndrome

MMR

:   Mismatch repair

*path_MLH1*

:   Pathogenic (disease-causing) variant of the *MLH1* gene

*path_MSH2*

:   Pathogenic (disease-causing) variant of the *MSH2* gene

*path_MSH6*

:   Pathogenic (disease-causing) variant of the *MSH6* gene

*path_PMS2*

:   Pathogenic (disease-causing) variant of the *PMS2* gene
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